FibroGen, Inc.

How big is FibroGen, Inc.?

As of Jun 18, FibroGen, Inc. has a market capitalization of 23.77 million, with net sales of 102.85 million and a net profit of -58.05 million over the last four quarters. Shareholder's funds are -225.60 million, and total assets are 214.53 million.

As of Jun 18, FibroGen, Inc. has a market capitalization of 23.77 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 102.85 million, while the sum of net profit for the same period is -58.05 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -225.60 million, and total assets amount to 214.53 million.

What does FibroGen, Inc. do?

FibroGen, Inc. is a biopharmaceutical company focused on developing first-in-class therapeutics. As of March 2025, it reported net sales of $3 million and a net loss of $17 million, with a market cap of $23.77 million.

Overview:<BR>FibroGen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class therapeutics in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -17 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 23.77 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.27<BR>- Return on Equity: 17.74%<BR>- Price to Book: -0.11<BR><BR>Contact Details:<BR>- Address: 409 Illinois St, SAN FRANCISCO CA: 94158-2509<BR>- Tel: 1 415 9781200<BR>- Website: http://www.fibrogen.com

Should I buy, sell or hold FibroGen, Inc.?

Who are in the management team of FibroGen, Inc.?

As of March 2022, the management team of FibroGen, Inc. includes Chairman James Schoeneck, CEO Enrique Conterno, Lead Independent Director Thomas Kearns, and Directors Aoife Brennan, Benjamin Cravatt, Suzanne Blaug, and Jeffrey Edwards. They oversee the company's strategic direction and operations.

As of March 2022, the management team of FibroGen, Inc. includes the following individuals:<BR><BR>- Mr. James Schoeneck, Chairman of the Board<BR>- Mr. Enrique Conterno, Chief Executive Officer and Director<BR>- Mr. Thomas Kearns, Lead Independent Director<BR>- Dr. Aoife Brennan, Director<BR>- Dr. Benjamin Cravatt, Director<BR>- Ms. Suzanne Blaug, Independent Director<BR>- Mr. Jeffrey Edwards, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is FibroGen, Inc. overvalued or undervalued?

As of March 2, 2020, FibroGen, Inc. is considered overvalued and risky due to negative valuation ratios and underperformance compared to peers and the S&P 500.

As of 2 March 2020, the valuation grade for FibroGen, Inc. moved from fair to risky, indicating a deteriorating outlook. The company appears to be overvalued given its negative valuation ratios, including an EV to EBITDA of -3.19 and a Price to Book Value of -0.15. Additionally, its P/E ratio is not applicable due to the company being loss-making, further underscoring its financial challenges.<BR><BR>In comparison to peers, FibroGen's valuation ratios are significantly worse, with Chimerix, Inc. showing a P/E of -8.6897 and EV to EBITDA of -6.6011, while CytomX Therapeutics, Inc. stands out with a very attractive P/E of 7.4924. FibroGen's stock has underperformed against the S&P 500, with a year-to-date return of -14.03% compared to the index's 12.22%, reinforcing the notion that the company is currently overvalued.

Is FibroGen, Inc. technically bullish or bearish?

As of August 8, 2025, FibroGen, Inc. shows a bullish technical trend overall, supported by positive weekly momentum indicators, but caution is advised due to mixed signals from daily moving averages and underperformance against the S&P 500.

As of 8 August 2025, the technical trend for FibroGen, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish and the KST is also bullish, indicating positive momentum. However, the daily moving averages are mildly bearish, which suggests some short-term weakness. The Bollinger Bands show a mildly bullish stance on the weekly but bearish on the monthly, indicating mixed signals. The stock has underperformed against the S&P 500 over the year, with a return of 8.38% compared to the S&P's 17.14%. Overall, the technical stance is bullish, but caution is warranted due to mixed signals in shorter time frames.